- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05607108
A Study of ZEN003694 in People With Squamous Cell Lung Cancer
Phase 2 Trial of ZEN003694 in Squamous Cell Lung Cancer Patients Harboring NSD3 Amplification
The purpose of this study is to find out whether ZEN003694 is an effective treatment for people with advanced squamous cell lung cancer with a mutation in the NSD3 gene.
ZEN003694 is a type of drug called a BET inhibitor. Researchers think ZEN003694 may help here because the drug works by blocking a group of proteins called bromodomain and extra-terminal (BET) proteins, which may counteract the effect of NSD3 on tumor growth. Blocking these proteins may slow or stop the growth of the cancer.
Study Overview
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Paul Paik, MD
- Phone Number: 646-608-3759
- Email: paikp@mskcc.org
Study Contact Backup
- Name: Mark Kris, MD
- Phone Number: 646-608-3914
Study Locations
-
-
New Jersey
-
Basking Ridge, New Jersey, United States, 07920
- Recruiting
- Memorial Sloan Kettering at Basking Ridge Limited Protocol Activities
-
Contact:
- Paul Paik, MD
- Phone Number: 646-608-3759
-
Middletown, New Jersey, United States, 07748
- Recruiting
- Memorial Sloan Kettering Monmouth (All Protocol Activities)
-
Contact:
- Paul Paik, MD
- Phone Number: 646-608-3759
-
Montvale, New Jersey, United States, 07645
- Recruiting
- Memorial Sloan Kettering Bergen (All protocol activities)
-
Contact:
- Paul Paik, MD
- Phone Number: 646-608-3759
-
-
New York
-
Commack, New York, United States, 11725
- Recruiting
- Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities )
-
Contact:
- Paul Paik, MD
- Phone Number: 646-608-3759
-
Harrison, New York, United States, 10604
- Recruiting
- Memorial Sloan Kettering Westchester (All Protocol Activities)
-
Contact:
- Paul Paik, MD
- Phone Number: 646-608-3759
-
New York, New York, United States, 10065
- Recruiting
- Memorial Sloan Kettering Cancer Center (All Protocol Activities)
-
Contact:
- Paul Paik, MD
- Phone Number: 646-608-3759
-
Uniondale, New York, United States, 11553
- Recruiting
- Memorial Sloan Kettering Nassau (All protocol activities)
-
Contact:
- Paul Paik, MD
- Phone Number: 646-608-3759
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically-confirmed squamous cell lung cancer
- Recurrent or metastatic disease
- Patients with previously treated asymptomatic brain metastases requiring no more than 10mg prednisone (or equivalent) are allowed. Patients with asymptomatic brain metastases ≤ 1cm not requiring more than 10mg prednisone (or equivalent) are allowed.
- Received prior first-line therapy: platinum-based chemotherapy and immunotherapy, given either concurrently or sequentially
- Eastern Cooperative Oncology Group (ECOG) PS 0-2
- Evidence of NSD3 gain or amplification by NGS, including but not limited to evidence of 8p11 gain or amplification as determined by MSK IMPACT or MSK ACCESS, or a commercially available molecular assay that is FDA authorized. Note: ctDNA testing, including but not limited to MSK ACCESS and Guardant and Foundation
Adequate laboratory parameters at Screening including:
- Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L
- Platelet count ≥ 100,000/mm^3
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 2.0 ULN (≤ 5 x ULN if liver metastases are present)
- Total bilirubin ≤ 1.25 x ULN
- Calculated or measured eGFR ≥ 40 ml/min or serum creatinine ≤ 1.5 x ULN
- Prothrombin time (PT), international normalized ratio (INR) and partial thromboplastin time (PTT) < 1.5 x ULN
- Ability to swallow capsules
- Use of corticosteroids is allowed up to a daily dose of 10 mg prednisone or equivalent provided that the dose has been stable for at least 2 weeks prior to the start of ZEN003694 dosing and will remain stable during ZEN003694 treatment.
- Females or males age ≥ 18 years (at time of signing informed consent)
- Female subjects may be enrolled if they are not of childbearing potential, permanently sterile or who are post-menopausal defined as no menses for at least 1 year without an alternative medical cause and FSH levels in the post-menopausal range. Female subjects of childbearing potential may be enrolled if they consistently and correctly use a highly effective form of contraception. Highly effective forms of contraception include: combined (estrogen and progestogen hormonal contraceptives (oral, intravaginal, transdermal) associated with inhibition of ovulation; progestogen-only hormonal contraception (oral, injectable, implantable) associated with inhibition of ovulation; intrauterine device (IUD); intrauterine hormone-releasing system (IUS); bilateral tubal occlusion; vasectomized partner; sexual abstinence. Female subjects should not donate eggs from the time point of study drug administration until at least 7 months thereafter.
- Males with partners of childbearing potential may be enrolled if they use a condom when having sex with a pregnant woman or with a non-pregnant female of childbearing potential from 21 days before the first dose of study drug through 4 months after the last dose of study drug, and males should not donate sperm from the time point of study drug administration until at least 4 months thereafter.
Contraception should be considered for a non-pregnant female partner of childbearing potential
- Females of childbearing potential must have a negative serum or urine pregnancy test before the first dose of study drugs and must agree to pregnancy tests during the study.
- Females may not be breast-feeding at the first dose of study drugs, during study participation or through 7 months after the last dose of study drugs
Exclusion Criteria:
- Have previously received an investigational BET inhibitor
- Have received prior systemic anti-cancer therapy or investigational therapy within 2 weeks or five half-lives, whichever is shorter, prior to the first dose of study drug
- Radiation therapy within 2 weeks of first dose of study drug
- Currently receiving medications known to be strong inducers or inhibitors of CYP3A4 and substrates of CYP1A2 with a narrow therapeutic window. Strong inducers and inhibitors of CYP3A4 and CYP1A2 substrates with narrow therapeutic ranges must be discontinued at least 7 days prior to the first administration of study drug.
- Left ventricular ejection fraction less than the lower of 50% or the lower limit of institution's normal range
- QTcF interval > 470 msec
- Known impaired cardiac function or clinically significant cardiac disease such as uncontrolled supraventricular arrhythmia, ventricular arrhythmia requiring therapy, or uncontrolled congestive heart failure (New York Heart Association functional class III or IV)
- Myocardial infarction or unstable angina within 6 months prior to the first administration of study drug
- Other clinically significant co-morbidities, such as uncontrolled pulmonary disease, active CNS disease, active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy, or any other condition that could compromise safety or the patient's participation in the study
- Other known active cancer requiring therapy at time of study entry
- Historically positive (screening tests not required) for human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) or with active infections. HBV positivity defined by positive hepatitis B surface antigen (HBsAg). HCV positivity defined as positive HCV viral load.
- Major surgery other than diagnostic surgery, dental surgery or stenting within 4 weeks prior to the first administration of study drug
- History of congenital or other deficiency in platelet function, or any known inherent or acquired coagulopathy, including current anticoagulation therapy (except for low-dose warfarin for port patency)
- Current or anticipated use within 7 days prior to the first administration of study drug, or during the study, of strong P-gp inhibitors.
- Use of oral Factor Xa inhibitors (i.e., rivaroxaban, apixaban, betrixaban, edoxaban otamixaban, letaxaban, eribaxaban) and Factor IIa inhibitors (i.e., dabigatran). Low molecular weight heparin is allowed. Note: except for subjects on anticoagulant therapy who must have PT-INR within therapeutic range as deemed appropriate by the Investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ZEN003694
All patients enrolled on the study will undergo treatment with ZEN003694 60mg po qd on a 5 days on/2 days off schedule in an every 21-day cycle.
All assessments, including drug dosing, have a window of +/- 7 days unless otherwise noted.
|
ZEN003694 60mg po qd on a 5 days on 2 days off schedule in an every 21-day cycle
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
overall response rate (ORR)
Time Frame: 2 years
|
Response to ZEN003694 will be determined using the sum unidimensional measurements of the target lesions present on the scan.
Unidimensional measurement rules will adhere to RECIST 1.1 guidelines.(6)
Classification of response will be categorized by RECIST 1.1 (CR, PR, SD, PD).
|
2 years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Paul Paik, MD, Memorial Sloan Kettering Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 22-286
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Squamous Cell Lung Cancer
-
National Cancer Institute (NCI)Active, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Unresectable Lung Non-Small Cell Carcinoma | Unresectable Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic...United States
-
UNC Lineberger Comprehensive Cancer CenterNot yet recruitingSquamous Cell Carcinoma of Head and Neck | Squamous Non-small Cell Lung Cancer | Squamous Cell Lung CancerUnited States
-
National Cancer Institute (NCI)Not yet recruitingHead and Neck Cancer | Lung Cancer | Head and Neck Squamous Cell Carcinoma | Squamous Non-small Cell Lung Cancer | Sinonasal Cancer | Head and Neck CarcnimonaUnited States
-
University Hospital RegensburgThe Anticancer FundUnknownNon-Small Cell Lung Cancer | Squamous Cell Lung Cancer | Non-Squamous Cell Lung CancerGermany
-
Roswell Park Cancer InstituteRecruitingMetastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Recurrent Head and Neck Squamous... and other conditionsUnited States
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnHead and Neck Squamous Cell Carcinoma | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1... and other conditionsUnited States
-
National Cancer Institute (NCI)RecruitingLung Non-Small Cell Carcinoma | Lung Non-Small Cell Squamous Carcinoma | Lung Non-Squamous Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8United States, Guam
-
Seagen Inc.Merck Sharp & Dohme LLCTerminatedMelanoma | Small Cell Lung Cancer | Prostate Cancer | Gastric Adenocarcinoma | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Gastroesophageal Junction Adenocarcinoma | Non-small Cell Lung Cancer, Squamous | Non-small Cell Lung Cancer, Non-squamousUnited States, Korea, Republic of, Italy, United Kingdom, Australia, Taiwan
-
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.Shandong Cancer Hospital and InstituteRecruitingBreast Cancer | Small Cell Lung Cancer | Colorectal Cancer | Advanced Solid Tumor | Non-small Cell Lung Cancer | Squamous Cell Cancer of Head and NeckChina
-
Peking University First HospitalMerck Sharp & Dohme LLCNot yet recruitingAdvanced Non-squamous Non-small-cell Lung Cancer | Metastatic Non-squamous Non Small Cell Lung Cancer | Recurrent Non-Squamous Non-Small Cell Lung CancerChina
Clinical Trials on ZEN003694
-
Zenith EpigeneticsCompletedMetastatic Castration-Resistant Prostate CancerUnited States
-
Zenith EpigeneticsEnrolling by invitation
-
Zenith EpigeneticsCompletedMetastatic Castration-Resistant Prostate CancerUnited States
-
Zenith EpigeneticsAstellas Pharma Inc; Newsoara Biopharma Co., Ltd.RecruitingMetastatic Castration-Resistant Prostate CancerUnited States, China
-
Haider MahdiPfizer; Zenith EpigeneticsRecruitingOvarian Cancer | Fallopian Tube Cancer | Peritoneal CancerUnited States
-
Haider MahdiGlaxoSmithKline; Zenith EpigeneticsRecruitingOvarian Cancer | Recurrent Solid TumorsUnited States
-
Zenith EpigeneticsPfizer; Newsoara Biopharma Co., Ltd.TerminatedTriple Negative Breast CancerUnited States, Belgium, China, Spain
-
National Cancer Institute (NCI)RecruitingMalignant Solid Neoplasm | Breast Carcinoma | NUT CarcinomaUnited States
-
Rahul AggarwalMerck Sharp & Dohme LLC; U.S. Army Medical Research and Development Command; Zenith...RecruitingCastration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma | Metastatic Prostate Small Cell CarcinomaUnited States
-
National Cancer Institute (NCI)RecruitingAdvanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States